Safety and tolerability profile of the adenosine A2A receptor antagonist BIIB014 in Parkinson's disease: Pooled analysis of two placebo-controlled 8-week studies

被引：0

|

作者：

Papapetropoulos, S.

Borgohain, R.

Kellet, M.

Giladi, N.

Tomic, D.

Coppell, A.

Zhu, Y.

Barnard, J.

Miller, L.

O'Neill, G. N.

机构：

来源：

MOVEMENT DISORDERS | 2010年 / 25卷 / 07期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

367

引用

收藏

页码：S304 / S304

页数：1

相关论文

共 50 条

[41] Safety, Tolerability, And Efficacy Of NE3107 From A Phase 2, Double-Blind, Placebo-Controlled Study In Levodopa/Carbidopa-Treated Patients With Parkinson's Disease
Ahlem, Clarence
Reading, Christopher
Djan, Joseph
Palumbo, Joseph
NEUROLOGY, 2023, 100 (17)
[42] Efficacy and safety of memantine in patients with moderate-to-severe Alzheimer's disease: results of a pooled analysis of two randomized, double-blind, placebo-controlled trials in Japan
Nakamura, Yu
Kitamura, Shin
Homma, Akira
Shiosakai, Kazuhito
Matsui, Daiju
EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (07) : 913 - 925
[43] Desvenlafaxine 50 and 100 mg/d in the Treatment of Major Depressive Disorder: An 8-Week, Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial and a Post Hoc Pooled Analysis of Three Studies
Tourian, Karen A.
Padmanabhan, Krishna
Groark, James
Brisard, Claudine
Farrington, Deborah
CLINICAL THERAPEUTICS, 2009, 31 : 1405 - 1423
[44] A phase 2, 8-week, multi-center, randomized double-blind, placebo controlled, parallel group study evaluating the efficacy, tolerability and safety of [s,s] - Reboxetine (PNU-165442G) for stress urinary incontinence in women
Zinner, Norman
Scholfield, David
Soma, Koshika
Darekar, Amanda
Grant, Lee
Mills, Ian
JOURNAL OF UROLOGY, 2008, 179 (04): : 569 - 570
[45] Pharmacokinetics, Safety, and Tolerability of Fevipiprant (QAW039), a Novel CRTh2 Receptor Antagonist: Results From 2 Randomized, Phase 1, Placebo-Controlled Studies in Healthy Volunteers (vol 5, pg 306, 2016)
Erpenbeck, V. J.
Vets, E.
Gheyle, L.
Osuntokun, W.
Larbig, M.
Neelakantham, S.
Sandham, D.
Dubois, G.
Elbast, W.
Goldsmith, P.
Weiss, M.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2020, 9 (07): : 889 - 890
[46] Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial
Wilkinson, David
Windfeld, Kristian
Colding-Jorgensen, Eskild
LANCET NEUROLOGY, 2014, 13 (11): : 1092 - 1099
[47] SAFETY PROFILE OF COLLAGENASE CLOSTRIDIUM HISTOLYTICUM IN THE TREATMENT OF PEYRONIE'S DISEASE WHEN PENILE CURVATURE ≥30° OR <30°: TWO DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 STUDIES
Hellstrom, Wayne
Tan, Ronny
Ling, Yang
Liu, Genzhou
Kaufman, Gregory
Seftel, Allen
JOURNAL OF SEXUAL MEDICINE, 2014, 11 : 169 - 169
[48] Randomized, placebo-controlled, double-blind, two-period cross-over study to evaluate the safety, tolerability, and efficacy of a novel treatment combination for levodopa induced dyskinesia in Parkinson's Disease (BUS-PD)
Chung, K.
Lobb, B.
O'Connor, S.
MOVEMENT DISORDERS, 2019, 34 : S35 - S36
[49] Safety of istradefylline (KW-6002) as adjunctive levodopa therapy in Parkinson's disease with motor complications: A combined meta-analysis of phase IIb and phase III placebo-controlled studies in Japan
Kondo, T.
Mizuno, Y.
MOVEMENT DISORDERS, 2012, 27 : S124 - S125
[50] evoke and evoke plus : design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease
Cummings, Jeffrey L.
Atri, Alireza
Feldman, Howard H.
Hansson, Oskar
Sano, Mary
Knop, Filip K.
Johannsen, Peter
Leon, Teresa
Scheltens, Philip
ALZHEIMERS RESEARCH & THERAPY, 2025, 17 (01)

← 1 2 3 4 5 →